Anaptys Announces Participation in Upcoming Investor Conferences
SAN DIEGO, Nov. 10, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with Tesaro, a GSK company, and Quimilza (imsidolimab) with Vanda, today announced that members of its executive team are scheduled to participate in multiple upcoming investor conferences:
UBS Global Biopharma Conference 2026, London
- Format – Fireside chat
- Date and Time – Tuesday, November 17, 2026 at 4:40pm GMT / 11:40am ET
- Participant – Daniel Faga, president and chief executive officer
Piper Sandler 38th Annual Healthcare Conference, New York
- Format – Fireside chat and one-on-one investor meetings
- Date and Time – Wednesday, December 2, 2026 at 8:00am ET
- Participant – Chris Murphy, chief financial officer
9th Annual Evercore Healthcare Conference, Miami
- Format – Fireside chat
- Date and Time – Wednesday, December 2, 2026 at 10:50am ET
- Participant – Daniel Faga, president and chief executive officer
Live webcasts of the fireside chats will be available on the investor section of the Anaptys website at https://ir.anaptysbio.com/presentations-and-events. Replays of the webcasts will be available for at least 30 days following the events.
About Anaptys
Anaptys manages the financial collaborations for Jemperli with GSK and Quimilza with Vanda, with a focus on protecting and returning the value of its royalties to shareholders. To learn more, visit www.AnaptysBio.com or follow us on LinkedIn.
Contact:
Chris Murphy
Chief Financial Officer
investors@anaptysbio.com

The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular

The 10 Best Dividend Stocks

5 Stocks to Buy After Earnings

2 5-Star Stocks to Buy at Big Discounts

Tech Stocks Suffer Worst Week Since 2020 as Anthropic Faces Day Two Decline


